Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Arix Bioscience : Artios and Merck KGaA announce global strategic collaboration

12/04/2020 | 05:41am EDT

LONDON - Arix Bioscience plc ('Arix', LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company Artios Pharma Limited ('Artios'), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, and Merck KGaA, Darmstadt, Germany ('Merck KGaA'), a leading science and technology company, today announced a global three-year strategic research collaboration to discover and develop multiple precision oncology drugs.

As part of the agreement, Artios will receive a payment of US$30 million in the form of an upfront and near-term payments. Merck KGaA shall have the right to opt into exclusive development of compounds on up to eight targets. If Merck KGaA chooses to exercise the option, subject to double digit option fees, Artios will be eligible to receive up to US$860 million per target, in addition to up to double digit royalty payments on net sales of each product commercialised by Merck KGaA. Subject to certain conditions, Artios has opt-in rights for joint development and commercialisation with Merck KGaA for the programmes.

Under the terms of the agreement, the companies will leverage Artios' proprietary nuclease targeting discovery platform to jointly identify multiple synthetic lethal targets for precision oncology drug candidates. The collaboration does not include Artios' lead programmes, Pol and ATR inhibitors, for which Artios will retain all rights.

Arix is the largest shareholder in Artios, with a 12.7% ownership stake on a fully diluted basis.

'Artios is a global powerhouse in DDR. Together with Merck KGaA's significant expertise and R&D resources, the collaboration will identify and develop precision oncology medicines targeting nucleases. As early investors and the largest shareholder in Artios, we are proud of the company's success. It is a testament to its leadership team and strategy in developing a unique discovery platform of novel DNA repair nuclease inhibitors and targets, which will bring real impact to cancer patients.'


Charlotte Parry

Tel: +44 (0)20 7290 1072

Email: charlotte@arixbioscience.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

About Artios Pharma Limited

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company, founded by SV Health Investors in 2016, is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and the National Centre for Biomolecular Research at Masaryk University in the Czech Republic. Artios is building a pipeline of nextgeneration DDR programmes to target hard to treat cancers. It is backed by blue chip investors including: AbbVie Ventures, Andera Partners (formerly EdRIP), Arix Bioscience plc, IP Group plc, LSP, M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with offices in New York City, USA.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of EUR 16.2 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck KGaA, Darmstadt, Germany's technological and scientific advances. This is how Merck KGaA, Darmstadt, Germany has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck KGaA, Darmstadt, Germany holds the global rights to the Merck KGaA, Darmstadt, Germany name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
ARIX BIOSCIENCE PLC 0.00% 159.5 Delayed Quote.-27.17%
MERCK KGAA 2.81% 201.3 Delayed Quote.39.51%
09/20PRESS RELEASE : Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific O..
09/03VC DAILY : Question: What Is Driving Startup -2-
09/02ARIX BIOSCIENCE : To Invest $11 Million In Disc Medicine
09/02Arix Bioscience participates in USD90 million Series B financing for Disc Medicine
09/02Disc Medicine, Inc. announced that it has received $90 million in funding from a group ..
09/01Total Voting Rights
08/31Transaction in own shares
08/16Transaction in own shares
08/16Director/PDMR Shareholding
08/13Transaction in own shares
More news
Sales 2021 0,50 M 0,68 M 0,68 M
Net income 2021 37,7 M 51,5 M 51,5 M
Net cash 2021 146 M 199 M 199 M
P/E ratio 2021 5,52x
Yield 2021 -
Capitalization 199 M 272 M 272 M
EV / Sales 2021 107x
EV / Sales 2022 87,5x
Nbr of Employees 12
Free-Float 72,2%
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 1,60 GBX
Average target price 221,50 GBX
Spread / Average Target 13 787%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Giles Francis Bertram Kerr Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
INVESTOR AB (PUBL)29.44%68 017
HAL TRUST30.40%15 279
LIFCO AB (PUBL)55.32%12 783